Aethlon Medical Prices $4.7M Public Offering

SAN DIEGO, May 15, 2024—Aethlon Medical, Inc. (Nasdaq: AEMD), a company specializing in medical therapeutics, has announced the pricing for a public offering involving 8,100,000 shares of its common stock (or alternatively, pre-funded warrants), along with Class A and Class B warrants for purchasing up to 8,100,000 shares of common stock each. The combined price for the public offering is set at $0.58 per share or pre-funded warrant, including the accompanying warrants. These warrants come with an exercise price of $0.58 per share and can be exercised immediately upon issuance. The Class A warrants will expire five years from the original issuance date, while the Class B warrants will expire one year from the original issuance date. The expected closure of the offering is around May 17, 2024, pending customary closing conditions.

Maxim Group LLC is serving as the exclusive placement agent for this offering. The gross proceeds from the offering are projected to be approximately $4.7 million before accounting for the placement agent's fees and other expenses. The company plans to allocate the net proceeds for various general corporate purposes, including clinical trial costs, research and development, capital expenditures, and working capital.

The securities are being offered via a registration statement on Form S-1, as amended (File No. 333-278188), which the Securities and Exchange Commission (SEC) declared effective on May 15, 2024. The offering will be conducted strictly by the means of a prospectus that forms part of the active registration statement. A preliminary prospectus about the offering has been filed with the SEC. Once available, electronic copies of the final prospectus can be accessed on the SEC's website.

Aethlon Medical is engaged in developing the Hemopurifier, a clinical-stage immunotherapeutic device designed to tackle cancer and severe viral infections, and is also applicable in organ transplantation. The Hemopurifier has demonstrated its ability to remove life-threatening viruses in human studies and harmful exosomes in pre-clinical studies. This technology uses a proprietary lectin-based approach, potentially applicable in cancer treatment where exosomes can contribute to immune suppression and metastasis. The Hemopurifier is designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA) for treating patients with advanced or metastatic cancer who do not respond to or cannot tolerate standard therapies. It also holds FDA Breakthrough Device designation and an open Investigational Device Exemption for treating life-threatening viruses that lack approved therapies.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!